Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-19 vaccine - AJ Vaccines

Drug Profile

COVID-19 vaccine - AJ Vaccines

Alternative Names: Coronavirus vaccine - AJ Vaccines

Latest Information Update: 17 Mar 2020

At a glance

  • Originator AJ Vaccines
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 06 Mar 2020 Early research in COVID-2019 infections (Prevention) in Denmark (Parenteral)
  • 06 Mar 2020 AJ Vaccines announces intention to launch COVID-2019 vaccine in 2021

Development Overview

Introduction

COVID-19 vaccine is being developed by AJ Vaccines for prevention against the coronavirus (COVID-19) infections. The company is utilising its modern antigen technology that allows for the production of vaccines combining high protection with a low reactogenicity and favourable safety profile as compared with some of the more traditional vaccines. Early research is underway in Denmark.

Key Development Milestones

In March 2020, AJ Vaccines announced intention to launch COVID-2019 vaccine in 2021 [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research Denmark Parenteral / unspecified AJ Vaccines 06 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
AJ Vaccines Originator Malaysia
AJ Vaccines Owner Malaysia

Future Events

Expected Date Event Type Description Updated
31 Dec 2021 Regulatory Status AJ Vaccines announces intention to launch COVID-2019 vaccine in 2021 [1] 17 Mar 2020

Development History

Event Date Update Type Comment
06 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in Denmark (Parenteral) [1] Updated 17 Mar 2020
06 Mar 2020 Regulatory Status AJ Vaccines announces intention to launch COVID-2019 vaccine in 2021 [1] Updated 17 Mar 2020

References

  1. AJ Vaccines To Develop Vaccine for COVID-19.

    Media Release
Back to top